The First School of Clinical Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, Jiangsu Province, China.
School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, Jiangsu Province, China.
J Ethnopharmacol. 2018 Jun 28;220:228-238. doi: 10.1016/j.jep.2018.01.007. Epub 2018 Jan 6.
Gathering three ancient formulas, traditional Chinese medicine Bu-Shen-Tong-Luo decoction (BSTLD) has been used to treat postmenopausal osteoporosis (PMO) at the Jiangsu Province Hospital of Chinese Medicine for decades. However, the effect of BSTLD on angiogenesis and bone resorption as well as its possible mechanism are still unknown.
This study was aimed to evaluate the preventive effect of BSTLD on ovariectomy-induced bone loss and vasculature disorder, and to investigate the possible bone protection mechanism of BSTLD in inhibiting bone resorption by enhancing angiogenesis signaling in ovariectomy-induced osteoporosis of rats.
The animal experiment was divided into five groups. Rats underwent either sham surgery with intact ovaries (SHAM, n = 10) or bilateral ovariectomy (OVX, n = 40). OVX rats were randomly divided into four groups and gavaged by water (vehicle, 12 mL/kg, n = 10), BSTLD (6 g/kg, n = 10), BSTLD (12 g/kg, n = 10) and 17β-estradiol (E2, 100 μg/kg, n = 10) daily for 12 weeks, respectively. The bone loss and microstructure of the distal femur were observed using micro-computed tomography (μCT). The biomechanical parameters of the femur were detected using three-point bending tests. The distribution of osteoclasts and endothelial cells were analyzed by immunohistochemistry. The mRNA and protein levels of angiogenesis-related hypoxia-inducible factor-1α (HIF-1α) and vascular endothelial growth factor (VEGF), as well as osteoclast activation-related signaling calcitonin receptor (CALCR), cathepsin K (CTSK), receptor activator of NF-κB ligand (RANKL), osteoprotegerin (OPG), and β-catenin were assayed by RT-PCR or Western blot.
BSTLD protected trabecular bone mass density and trabecular bone microstructure from ovariectomy-induced osteoporosis in rats. BSTLD significantly reduced mRNA and protein levels of calcitonin receptor and CTSK in femoral metaphysis and inhibited bone resorption in ovariectomized rats. Furthermore, BSTLD stabilized HIF-1α activity and subsequently increased VEGF expression to enhance angiogenesis and modulated RANKL/OPG signaling in this animal model.
These results demonstrated that BSTLD reduced osteoclasts activation and bone resorption in ovariectomy-induced osteoporosis. Bone protection by BSTLD may be associated with its stimulation of HIF-1α/VEGF angiogenesis signaling and suppression of RANKL/OPG ratio. This study may provide evidence that BSTLD treats postmenopausal osteoporosis, especially with micro-circulation complication.
ETHNOPHARMACOLOGICAL 相关性:江苏省中医院几十年来一直使用中药补肾通络汤(BSTLD)来治疗绝经后骨质疏松症(PMO)。然而,BSTLD 对血管生成和骨吸收的影响及其可能的机制仍不清楚。
本研究旨在评估 BSTLD 对去卵巢诱导的骨丢失和血管紊乱的预防作用,并通过增强去卵巢诱导骨质疏松大鼠的血管生成信号来抑制骨吸收,探讨 BSTLD 抑制骨吸收的可能骨保护机制。
动物实验分为五组。大鼠行假手术(SHAM,n=10)或双侧卵巢切除术(OVX,n=40)。OVX 大鼠随机分为四组,分别灌胃水(载体,12ml/kg,n=10)、BSTLD(6g/kg,n=10)、BSTLD(12g/kg,n=10)和 17β-雌二醇(E2,100μg/kg,n=10),每日 1 次,共 12 周。通过微计算机断层扫描(μCT)观察远端股骨的骨丢失和微观结构。通过三点弯曲试验检测股骨的生物力学参数。通过免疫组织化学分析破骨细胞和内皮细胞的分布。通过 RT-PCR 或 Western blot 测定血管生成相关缺氧诱导因子-1α(HIF-1α)和血管内皮生长因子(VEGF)以及破骨细胞激活相关信号钙敏感受体(CALCR)、组织蛋白酶 K(CTSK)、核因子-κB 受体激活配体(RANKL)、骨保护素(OPG)和β-连环蛋白的 mRNA 和蛋白水平。
BSTLD 可预防去卵巢诱导的大鼠骨小梁骨量密度和骨小梁微观结构的骨质疏松症。BSTLD 可显著降低股骨骺板 CALCR 和 CTSK 的 mRNA 和蛋白水平,并抑制去卵巢大鼠的骨吸收。此外,BSTLD 稳定 HIF-1α 活性,继而增加 VEGF 表达,以增强血管生成,并调节该动物模型中的 RANKL/OPG 信号。
这些结果表明,BSTLD 可减少去卵巢诱导的骨质疏松症中的破骨细胞激活和骨吸收。BSTLD 对骨的保护作用可能与其刺激 HIF-1α/VEGF 血管生成信号和抑制 RANKL/OPG 比值有关。本研究可为 BSTLD 治疗绝经后骨质疏松症,特别是伴有微循环并发症提供依据。